More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...
Eli Lilly announces one-year histologic mirikizumab data
Eli Lilly announced data demonstrating more patients with moderately to severely active Crohn’s disease treated with ...
PMLiVE5d
Eli Lilly’s mirikizumab shows promise in phase 3 Crohn’s disease study
Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...
The Pharma Letter5d
Mirikizumab bests ustekinumab in Phase III Crohn's disease study
US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...
Lilly Reports 1-year Histologic Data From Phase 3 VIVID-1 Study Of Mirikizumab In Crohn's Disease
(RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.
Pharmabiz5d
Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...
Eli Lilly and Company: Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyon ...
Nasdaq6d
Lilly Reports 1-year Histologic Data From Phase 3 VIVID-1 Study Of Mirikizumab In Crohn's Disease
(RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.
Investing6d
Mirikizumab shows promise in Crohn's disease study
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) has unveiled new data indicating that mirikizumab, its investigational treatment for Crohn's disease, achieved a higher rate of histologic ...